Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus

Gene Therapy

Volumn 13, Issue 13, 2006, Pages 1037-1047

  Schambach, A ^a   Schiedlmeier, B ^a   Kuhlcke K ^b   Verstegen, M ^a,c   Margison, G P ^d   Li, Z ^a   Kamino, K ^a   Bohne, J ^a   Alexandrov, A ^e   Hermann, F G ^f   von Laer, D ^f   Baum, Christopher ^a,g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b EUFETS AG   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e Fresenius Biotech   (Germany)

^f Cincinnati Children's Hospital Medical Center ^*  (Germany)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

AIDS; Chemotherapy; Gene transfer; HIV fusion inhibitors

Indexed keywords

ALKYLATING AGENT; ANTIVIRUS AGENT; HYBRID PROTEIN; M 87O; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; MUTANT PROTEIN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ARTIFICIAL MEMBRANE; BONE MARROW TRANSPLANTATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA MODIFICATION; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RETROVIRIDAE; TRANSDUCTION, GENETIC;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MURINAE;

EID: 33745219190     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302755     Document Type: Article

References (53)

1. Yang QE. Eradication of HIV in infected patients: Some potential approaches. Med Sci Monit 2004; 10: RA155-RA165.
2. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: Novel gene therapy approaches for AIDS. Gene Therapy 2005; 12: 467-476.
3. Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 2005; 11: 823-842.
4. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. New Engl J Med 2002; 346: 1185-1193.
5. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
6. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
7. Ott MG, Stein S, Koehl U, Schilz A, Kuhlcke K, Schmidt M et al. Gene therapy for X-linked chronic granulomatous disease. Blood 2004; 104: 120a, abstract 409.
8. Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001; 75: 3038-3042.
9. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002; 16: 2385-2390.
10. Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R et al. Inhibition of HIV-1 entry in cells expressing Gp41-derived peptides. J Virol 2004; 78: 568-575.
11. von Laer D, Hasselmann S, Hasselmann K. Impact of gene-modified T cells on HIV infection dynamics. J Theor Biol 2006; 238: 60-77.
12. Podsakoff GM, Engel BC, Carbonaro DA, Choi C, Smogorzewska EM, Bauer G et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005; 12: 77-86.
13. Engel BC, Kohn DB. Gene therapy for inborn and acquired immune deficiency disorders. Acta Haematol 2003; 110: 60-70.
14. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368-371.
15. Bordignon C, Roncarolo MG. Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol 2002; 3: 318-321.
16. Davis BM, Humeau L, Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther 2004; 9: 160-172.
17. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
18. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
19. Modlich U, Kustikova O, Schmidt M, Rudolph C, Meyer J, Li Z et al. Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
20. Kustikova OS, Fehse B, Düllmann J, Kamino K, von Neuhoff N, Schlegelberger B et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174.
21. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296-307.
22. Ragg S, Xu-Welliver M, Bailey J, D Souza M, Cooper R, Chandra S et al. Direct reversal of DNA damage by mutant methyl-transferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187-5195.
23. Jansen M, Sorg UR,.Ragg S, Flasshove M, Seeber S, Williams DA et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther 2002; 9: 737-746.
24. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005; 105: 997-1002.
25. Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003; 112: 1581-1588.
26. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 2003; 112: 1561-1570.
27. Pollok KE, Hartwell JR, Braber A, Cooper RJ, Jansen M, Ragg S et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 2003; 14: 1703-1714.
28. Hildinger M, Abel KL, Ostertag W, Baum C. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083-4089.
29. Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, Baum C. Context dependence of different modules for post-transcriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435-445.
30. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405-1413.
31. Fehse B, Kustikova OS, Bubenheim M, Baum C. Pois(s)on - it's a question of dose? Gene Therapy 2004; 11: 879-881.
32. Kustikova OS, Wahlers A, Kuehlcke K, Staehle B, Zander AR, Baum C et al. Dose finding with retroviral vectors: Correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 102: 3934-3937.
33. Hildinger M, Schilz A, Eckert HG, Bohn W, Fehse B, Zander A et al. Bicistronic retroviral vectors for combining myeloprotection with cell-surface marking. Gene Therapy 1999; 6: 1222-1230.
34. Qin S, Ward M, Raftopoulos H, Tang H, Bradley B, Hesdorffer C et al. Competitive repopulation of retrovirally transduced haemopoietic stem ceps. Br J Haematol 1999; 107: 162-168.
35. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti J-C, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell transplanted mice. Science 2004; 304: 104-107.
36. Haigwood NL. Predictive value of primate models for AIDS. AIDS Rev 2004; 6: 187-198.
37. Zielske SP, Gerson SL. Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: Lack of copy number selection by drug treatment. Mol Ther 2004; 9: 923-931.
38. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LM02-associated clonal T cell proliferation in two patients after gene therapy for SLID-X1. Science 2003; 302: 415-419.
39. Williams DA, Baum C. Medicine. Gene therapy - new challenges ahead. Science 2003; 302: 400-401.
40. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivras vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
41. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
42. Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M et al. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther 2003; 14: 509-519.
43. Vassilopoulos G, Trobridge G, Josephson NC, Russell DW. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 2001; 98: 604-609.
44. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198.
45. Kraunus J, Schaumann DHS, Meyer J, Modlich U, Fehse B, Brandenburg G et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Therapy 2004; 11: 1568-1578.
46. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA-methyltransferase in bone marrow cells. Mol Ther 2006; 13: 391-400.
47. Morita S, Kojima T, Kitamura T. Plat-E: An efficient and stable system for transient packaging of retroviruses, Gene Therapy 2000; 7: 1063-1070.
48. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96: 5215-5220.
49. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67: 6642-6647.
50. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385: 645-649.
51. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-1148.
52. Li Z, Schwieger M, Lange C, Kraunus J, Sun H, van den Akker E et al. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 2003; 31: 1206-1214.
53. Watson AJ, Margison GP. O6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 2000; 152: 49-61.